Metformin’s well-established anti-cancer mechanisms involve direct and indirect, AMPK-dependent and -independent inhibition of mammalian target of rapamycin (mTOR), which plays a significant role in promoting tumor proliferation as well as inhibiting apoptosis and autophagy. This evidence concerns the gene MTOR and cancer.